These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29969826)

  • 61. Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.
    Radtke J; Dietze N; Spetzler VN; Fischer L; Achilles EG; Li J; Scheidat S; Thaiss F; Nashan B; Koch M
    Transpl Infect Dis; 2016 Feb; 18(1):79-88. PubMed ID: 26707694
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A 3-month, Multicenter, Randomized, Open-label Study to Evaluate the Impact on Wound Healing of the Early (vs Delayed) Introduction of Everolimus in De Novo Kidney Transplant Recipients, With a Follow-up Evaluation at 12 Months After Transplant (NEVERWOUND Study).
    Manzia TM; Carmellini M; Todeschini P; Secchi A; Sandrini S; Minetti E; Furian L; Spagnoletti G; Pisani F; Piredda GB; Cappelli G; Tisone G
    Transplantation; 2020 Feb; 104(2):374-386. PubMed ID: 31335776
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
    Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
    Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Incidence of cytomegalovirus infection in seropositive kidney transplant recipients treated with everolimus: A randomized, open-label, multicenter phase 4 trial.
    Kaminski H; Kamar N; Thaunat O; Bouvier N; Caillard S; Garrigue I; Anglicheau D; Rérolle JP; Le Meur Y; Durrbach A; Bachelet T; Savel H; Coueron R; Visentin J; Del Bello A; Pellegrin I; Déchanet-Merville J; Merville P; Thiébaut R; Couzi L
    Am J Transplant; 2022 May; 22(5):1430-1441. PubMed ID: 34990047
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evolution of Renal Function in Renal Allograft Recipients Under Various Everolimus-Based Immunosuppressive Regimens.
    Skalioti C; Marinaki S; Darema M; Lionaki S; Antonakopoulos N; Zavos G; Boletis J
    Transplant Proc; 2015; 47(6):1705-10. PubMed ID: 26293038
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of everolimus plus minimized tacrolimus on kidney function in liver transplantation: REDUCE, a prospective, randomized controlled study.
    Gómez-Bravo M; Prieto Castillo M; Navasa M; Sánchez-Antolín G; Lladó L; Otero A; Serrano T; Jiménez Romero C; García González M; Valdivieso A; González-Diéguez ML; de la Mata M; Pons JA; Salcedo M; Rodrigo JM; Cuervas-Mons V; González Rodríguez A; Caralt M; Pardo F; Varo Pérez E; Crespo G; Rubin Á; Guilera M; Aldea A; Santoyo J
    Rev Esp Enferm Dig; 2022 Jun; 114(6):335-342. PubMed ID: 35469409
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Nashan B; Thaiss F
    Trials; 2016 Feb; 17():92. PubMed ID: 26888217
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
    Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study.
    Boillot O; Mayer DA; Boudjema K; Salizzoni M; Gridelli B; Filipponi F; Trunecka P; Krawczyk M; Clavien PA; Ducerf C; Margarit C; Margreiter R; Pallardo JM; Hoeckerstedt K; Pageaux GP
    Liver Transpl; 2005 Jan; 11(1):61-7. PubMed ID: 15690537
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Use of Everolimus-based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant.
    Malvezzi P; Jouve T; Rostaing L
    Exp Clin Transplant; 2016 Aug; 14(4):361-6. PubMed ID: 27041365
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Suppression of Allograft Fibrosis by Regulation of Mammalian Target of Rapamycin-Related Protein Expression in Kidney-Transplanted Recipients Treated with Everolimus and Reduced Tacrolimus.
    Nishioka S; Ishimura T; Endo T; Yokoyama N; Ogawa S; Fujisawa M
    Ann Transplant; 2021 Jan; 26():e926476. PubMed ID: 33431785
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression.
    Mourad G; Garrigue V; Squifflet JP; Besse T; Berthoux F; Alamartine E; Durand D; Rostaing L; Lang P; Baron C; Glotz D; Antoine C; Vialtel P; Romanet T; Lebranchu Y; Al Najjar A; Hiesse C; Potaux L; Merville P; Touraine JL; Lefrancois N; Kessler M; Renoult E; Pouteil-Noble C; Cahen R; Legendre C; Bedrossian J; Le Pogamp P; Rivalan J; Olmer M; Purgus R; Mignon F; Viron B; Charpentier B
    Transplantation; 2001 Sep; 72(6):1050-5. PubMed ID: 11579299
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
    Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Steroid avoidance with early intensified dosing of enteric-coated mycophenolate sodium: a randomized multicentre trial in kidney transplant recipients.
    Thierry A; Mourad G; Büchler M; Kamar N; Villemain F; Heng AE; Le Meur Y; Choukroun G; Toupance O; Legendre C; Lepogamp P; Kessler M; Merville P; Moulin B; Quéré S; Terpereau A; Chaouche-Teyara K; Touchard G
    Nephrol Dial Transplant; 2012 Sep; 27(9):3651-9. PubMed ID: 22645323
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids.
    Glotz D; Charpentier B; Abramovicz D; Lang P; Rostaing L; Rifle G; Vanrenterghem Y; Berthoux F; Bourbigot B; Delahousse M; Chalopin JM; Cassuto E; Lefrançois N
    Transplantation; 2010 Jun; 89(12):1511-7. PubMed ID: 20386144
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant.
    Pascual J; van Hooff JP; Salmela K; Lang P; Rigotti P; Budde K
    Transplantation; 2006 Jul; 82(1):55-61. PubMed ID: 16861942
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Tacrolimus reduction with everolimus addition for calcineurin inhibitor-induced arteriolopathy in kidney allografts.
    Miura M; Higashiyama H; Fukasawa Y; Itoh Y; Tamaki T
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():58-60. PubMed ID: 26031588
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
    Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
    Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A randomized trial comparing renal function in older kidney transplant patients following delayed versus immediate tacrolimus administration.
    Andrés A; Budde K; Clavien PA; Becker T; Kessler M; Pisarski P; Fornara P; Burmeister D; Hené RJ; Cassuto-Viguier E;
    Transplantation; 2009 Nov; 88(9):1101-8. PubMed ID: 19898206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.